GIST Recurrence Risk Underestimated 'in a Third of Patients'GIST Recurrence Risk Underestimated 'in a Third of Patients'
Many patients with resected gastrointestinal stromal tumors (GIST) are missing out on recommended adjuvant therapy. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Gastroenterology | Gastrointestinal Stromal Tumor (GIST) | Health | Hematology